Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma

被引：21

作者：

Einsele, H. ^{[1
]}

Knop, S. ^{[1
]}

Vogel, M. ^{[2
]}

Mueller, J. ^{[3
]}

Kropff, M. ^{[4
]}

Metzner, B. ^{[5
]}

Langer, C. ^{[6
]}

Sayer, H. ^{[7
]}

Jung, W. ^{[8
]}

Duerk, H. A. ^{[9
]}

Salwender, H. ^{[10
]}

Wandt, H. ^{[11
]}

Bassermann, F. ^{[12
]}

Gramatzki, M. ^{[13
]}

Roesler, W. ^{[14
]}

Wolf, H-H ^{[15
]}

Brugger, W. ^{[16
]}

Engelhardt, M. ^{[17
]}

Fischer, T. ^{[18
]}

Liebisch, P. ^{[6
]}

Straka, C. ^{[19
]}

机构：

[1] Julius Maximilians Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] Janssen Cilag GmbH, Neuss, Germany

[3] Acromion GmbH, Frechen, Germany

[4] Univ Klinikum Munster, Munster, Germany

[5] Klinikum Oldenburg Klin Onkol & Hamatol, Oldenburg, Germany

[6] Univ Klinikum Ulm, Zentrum Innere Med, Ulm, Germany

[7] Univ Hosp Jena, Jena, Germany

[8] Onkol Univ Med Gottingen, Gottingen, Germany

[9] St Marien Hosp Hamm Knappenstr, Hamm, Germany

[10] Asklepios Klin Altona, Hamburg, Germany

[11] Med Klin 5 Hamatol & Onkol, Nurnberg, Germany

[12] Tech Univ Munich, Med Klin, Munich, Germany

[13] Univ Klinikum Schleswig Holstein, Kiel, Germany

[14] Univ Klinkum Erlangen, Erlangen, Germany

[15] Univ Hosp Halle, Halle, Saale, Germany

[16] Schwarzwald Baar Klinikum, Villingen Schwenningen, Germany

[17] Univ Freiburg, Freiburg, Germany

[18] Otto von Guericke Univ, Magdeburg, Germany

[19] Schon Klin Starnberger See, Berg, Germany

来源：

LEUKEMIA | 2017年 / 31卷 / 06期

关键词：

STEM-CELL TRANSPLANTATION; INDUCTION; THERAPY; PHASE-3;

D O I：

10.1038/leu.2017.83

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1463 / 1466

页数：5

共 50 条

[1] Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma
H Einsele
S Knop
M Vogel
J Müller
M Kropff
B Metzner
C Langer
H Sayer
W Jung
H A Dürk
H Salwender
H Wandt
F Bassermann
M Gramatzki
W Rösler
H-H Wolf
W Brugger
M Engelhardt
T Fischer
P Liebisch
C Straka
Leukemia, 2017, 31 : 1463 - 1466
[2] Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma
Winnie Z. Y. Teo
Ian Y. E. Ong
Jason W. Y. Tong
Wan Li Ong
Adeline Lin
Fangfang Song
Bee Choo Tai
Melissa Ooi
Cinnie Yentia Seokojo
Yunxin Chen
Chandramouli Nagarajan
Wee Joo Chng
Sanjay de Mel
Current Hematologic Malignancy Reports, 2023, 18 : 190 - 200
[3] Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma
Teo, Winnie Z. Y.
Ong, Ian Y. E.
Tong, Jason W. Y.
Ong, Wan Li
Lin, Adeline
Song, Fangfang
Tai, Bee Choo
Ooi, Melissa
Seokojo, Cinnie Yentia
Chen, Yunxin
Nagarajan, Chandramouli
Chng, Wee Joo
de Mel, Sanjay
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2023, 18 (05) : 190 - 200
[4] Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
Jakubowiak, Andrzej J.
Kumar, Shaji
Medhekar, Rohan
Pei, Huiling
Lefebvre, Patrick
Kaila, Shuchita
He, Jianming
Lafeuille, Marie-Helene
Cortoos, Annelore
Londhe, Anil
Mavros, Panagiotis
Lin, Thomas S.
Usmani, Saad Z.
ONCOLOGIST, 2022, 27 (07): : E589 - E596
[5] Immunoglobulin Recovery after ASCT for Patients with Multiple Myeloma: Impact on Overall Survival and Progression-Free Survival
Jimenez-Zepeda, Victor
Duggan, Peter
Neri, Paola
Chaudhry, Ahsan
Tay, Jason
Bahlis, Nizar J.
BLOOD, 2016, 128 (22)
[6] Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma
Qin Yazhen
Lu Jin
Bao Li
Zhu Honghu
Li Jinlan
Li Lingdi
Lai Yueyun
Shi Hongxia
Wang Yazhe
Liu Yanrong
Jiang Bin
Huang Xiaojun
中华医学杂志(英文版), 2014, (09) : 1666 - 1671
[7] Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma
Qin Yazhen
Lu Jin
Bao Li
Zhu Honghu
Li Jinlan
Li Lingdi
Lai Yueyun
Shi Hongxia
Wang Yazhe
Liu Yanrong
Jiang Bin
Huang Xiaojun
CHINESE MEDICAL JOURNAL, 2014, 127 (09) : 1666 - 1671
[8] Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma
Daniele, Patrick
Mamolo, Carla
Cappelleri, Joseph C.
Bell, Timothy
Neuhof, Alexander
Tremblay, Gabriel
Musat, Mihaela
Forsythe, Anna
PLOS ONE, 2022, 17 (05):
[9] Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone
Wang, Jianxiang
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, C. S.
Rodriguez-Otero, Paula
Liberati, Anna Marina
Takamatsu, Hiroyuki
Lee, Jae Hoon
Dimopoulos, Meletios A.
Wroblewski, Susan
Carson, Robin
Qi, Ming
Wang, Jianping
Song, Yang
Jia, Bin
Yang, Xue
Liu, Wenyu
Li, Yunan
Zhang, Renyi
Hou, Jian
BLOOD, 2021, 138
[10] Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma
Caro, Jessica
Cairns, David
Menzies, Tom
Pawlyn, Charlotte
Boyle, Eileen M.
Morgan, Gareth
Cook, Gordon
Kaiser, Martin F.
Owen, Roger G.
Gregory, Walter M.
Jackson, Graham H.
Walker, Brian
Heaney, Jennifer Lj
Drayson, Mark T.
Davies, Faith E.
BLOOD, 2020, 136

← 1 2 3 4 5 →